SCHEMBL6441983

SCHEMBL6441983

CN1CCC(Oc2nc(N)nc(-c3ccco3)c2C#N)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 10/20 0.51
ADORA1 P30542 9/20 0.51
ADORA2B P29275 6/20 0.51
ALDH1A1 P00352 5/20 0.40
HPGD P15428 5/20 0.40
KDM4E B2RXH2 4/20 0.40
GAA P10253 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HRH3 Q9Y5N1 2/20 0.39
ADORA3 P0DMS8 3/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CCNA1 P78396 1/20 0.39
CASP1 P29466 2/20 0.38
HSD17B10 Q99714 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
MAPT P10636 1/20 0.38
CASP7 P55210 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6444565 0.90 ADORA2A (0.47) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL5046621 0.87 ADORA2A (0.55) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL6445683 0.86 ADORA2A (0.54) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL6443406 0.78 ADORA2A (0.64) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL6448539 0.77 ADORA2A (0.56) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL5044492 0.75 ADORA2A (0.60) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL5046844 0.75 ADORA1 (0.60) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL6445430 0.74 ADORA1 (0.50) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL6441656 0.73 ADORA1 (0.49) ADORA2AADORA1ADORA2BALDH1A1HPGD
SCHEMBL6442943 0.73 ADORA2A (0.67) ADORA2AADORA1ADORA2BALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.